# US 2021/0069341 A1 · Conjugated compounds comprising cysteine-engineered antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069341 A1
- Document ID: US20210069341A1
- Status: Published application
- Kind: A1
- Application number: 16/993,376
- Filed: 2020-08-14
- Published: 2021-03-11
- Earliest claimed: 2014-04-11
- Assignees: MedImmune, LLC
- Applicants: MedImmune, LLC
- Inventors: Changshou GAO; Godfrey RAINEY; Cuihua GAO
- Web page: https://patentgrep.com/patent/US20210069341A1

## CPC

- C07K 16/30: from tumour cells
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6817: {Toxins}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

## Claims

### Claim 1

A method for making a conjugate compound comprising:
(i) mutagenizing at least a nucleic acid sequence encoding an antibody or Fc fusion protein by inserting a codon encoding for a cysteine (C) between the codons encoding the amino acids at positions 239 and 240, wherein the amino acid position numbering is according to the EU index as set forth in Kabat;
(ii) expressing the cysteine-engineered antibody or Fc fusion protein;
(iii) isolating the cysteine-engineered antibody or Fc fusion protein; and
(iv) reacting at least one engineered cysteine group of the cysteine-engineered antibody or Fc fusion protein with a heterologous moiety.

### Claim 2

A method for making a conjugate compound comprising:
(i) operably linking a nucleic acid sequence encoding a variable heavy chain region or a heterologous protein to a nucleic acid sequence encoding an Fc region protein, wherein the nucleic acid sequence encoding the Fc region protein comprises:
at least a codon encoding a cysteine inserted between the codons encoding the amino acid at positions 239 and 240, wherein the amino acid position numbering is according to the EU index as set forth in Kabat;
(ii) expressing the cysteine-engineered antibody or Fc fusion protein;
(iii) isolating the cysteine-engineered antibody or Fc fusion protein; and
(iv) reacting at least one engineered cysteine group of the cysteine-engineered antibody or Fc fusion protein with a heterologous moiety.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cysteine-engineered antibody or Fc fusion protein further comprises at least one engineered cysteine amino acid selected from cysteine amino acid substitutions at amino acid position 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, or 439 wherein the amino acid position numbering is according to the EU index as set forth in Kabat.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the engineered cysteine amino acid is selected from cysteine amino acid substitutions at amino acid positions 241, 243, 251, 253, 258, 264, 271, 285, 288, 291, 296, 301, 307, 309, 311, 329, 385, 387, 433, or 435 and combinations thereof.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the engineered cysteine amino acid is selected from cysteine amino acid substitutions at amino acid positions 258, or 435 and combinations thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cysteine-engineered antibody or Fc fusion protein comprises:
a Cysteine (C) inserted between the Serine (S) located at position 239 and the Valine (V) located at position 240; and
(a) a Cysteine (C) substituting the Glutamic acid (E) located at position 258;
(b) a Cysteine (C) substituting the Histidine (H) located at position 435;
(c) a Cysteine (C) substituting the Arginine (R) located at position 435; or
(d) a combination thereof,
wherein the amino acid position numbering is according to the EU index as set forth in Kabat.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the Fc domain further comprises at least one engineered cysteine residue selected from cysteine amino acid substitutions at amino acid positions 239, 248, 254, 273, 279, 282, 284, 286, 287, 289, 297, 298, 312, 324, 326, 330, 335, 337, 339, 350, 355, 356, 359, 360, 361, 375, 383, 384, 389, 398, 400, 413, 415, 418, 422, 440, 441, 442, 443 and 446.

### Claim 8 (depends on 1)

The method according to claim 1, wherein each one of the heterologous moieties is conjugated to an engineered cysteine.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the Fc domain of the antibody or Fc fusion protein is a human IgG Fc domain, optionally selected from the group consisting of the IgG Fc domain of an IgG1, IgG2, IgG3, or IgG4.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the Fc fusion protein comprises an antigen binding domain selected from the group consisting of: (a) an scFv; (b) a diabody; (c) an Fd fragment; (d) an Fv fragment; (e) a TANDAB®; (f) a F(ab′)2 fragment; (g) a FCAB™, and (h) a F(ab) fragment.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the antibody is a monoclonal antibody, a bispecific antibody, a multispecific antibody, a chimeric antibody, a human antibody, or a humanized antibody.

### Claim 12 (depends on 1)

The method according to claim 1, wherein at least one heterologous moiety is a toxin, drug, radionuclide, immunomodulator, cytokine, lymphokine, chemokine, growth factor, tumor necrosis factor, hormone, hormone antagonist, enzyme, oligonucleotide, DNA, RNA, siRNA, RNAi, microRNA, peptide nucleic acid, photoactive therapeutic agent, anti-angiogenic agent, pro-apoptotic agent, non-natural amino acid, peptide, lipid, carbohydrate, scaffolding molecule, fluorescent tag, visualization peptide, biotin, serum half-life extender, capture tag, chelating agent, solid support, or a combination thereof, and wherein conjugation is at one of the engineered cysteines.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the drug is an auristatin, a tubulysin, a pyrrolobenzodiazepine (PBD), or a maytansinoid.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the drug is a pyrrolobenzodiazepine (PBD).

### Claim 15 (depends on 1)

The method according to claim 1, wherein the cysteine-engineered antibody or Fc fusion protein specifically binds to at least one target.

### Claim 16 (depends on 15)

The conjugate compound according to claim 15, wherein the target is a tumor antigen and the heterologous moiety is an antitumor agent.

### Claim 17

A nucleic acid encoding a cysteine-engineered antibody or Fc fusion protein, wherein the Fc domain of the antibody or Fc fusion protein comprises a cysteine amino acid insertion between positions 239 and 240, wherein the amino acid position numbering is according to the EU index as set forth in Kabat.

### Claim 18 (depends on 17)

A vector comprising the nucleic acid of claim 17.

### Claim 19 (depends on 17)

A host cell comprising the nucleic acid of claim 17.

### Claim 20 (depends on 18)

A host cell comprising the vector of claim 18.
